The Osteogenic Potential of Brown Seaweed Extracts by Walsh, Pamela et al.
The Osteogenic Potential of Brown Seaweed Extracts
Walsh, P., McGrath, S., McKelvey, S., Ford, L., Sheldrake, G., & Clarke, S. (2019). The Osteogenic Potential of
Brown Seaweed Extracts. Marine Drugs. https://doi.org/10.3390/md17030141
Published in:
Marine Drugs
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2019 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:05. Apr. 2019
marine drugs 
Article
The Osteogenic Potential of Brown Seaweed Extracts
Pamela J. Walsh 1,* , Susan McGrath 2, Steven McKelvey 3, Lauren Ford 1 , Gary Sheldrake 1
and Susan A. Clarke 3,*
1 School of Chemistry and Chemical Engineering, Queen’s University Belfast, David Keir Building,
Stranmillis Road, Belfast BT9 5AG, UK; L.ford@qub.ac.uk (L.F.); g.sheldrake@qub.ac.uk (G.S.)
2 School of Medicine, Dentistry & Biomedical Science, Queen’s University Belfast 97 Lisburn Road,
Belfast BT9 7BL, UK; smcgrath24@qub.ac.uk
3 School of Nursing and Midwifery, Queen’s University Belfast, MBC, 97 Lisburn Road, Belfast BT9 7BL, UK;
smckelvey04@qub.ac.uk
* Correspondence: pamela.walsh@qub.ac.uk (P.J.W.); s.a.clarke@qub.ac.uk (S.A.C.);
Tel.: +44-28-90-975570 (P.J.W.); +28-90-972171 (S.A.C.)
Received: 31 January 2019; Accepted: 21 February 2019; Published: 27 February 2019


Abstract: Marine drugs hold significantly more promise than their terrestrial counterparts, which
could help to solve the current shortfall in treatments for osteoporosis and other bone related diseases.
Fucoxanthin is the main carotenoid found in brown seaweed, and has many perceived health benefits,
including potential bone therapeutic properties. This study assessed the osteogenic potential of pure
fucoxanthin and crude extracts containing both fucoxanthin and phenolic fractions (also cited to
have osteogenic potential) isolated from two intertidal species of brown seaweed, Laminaria digitata
and Ascophyllum nodosum. In vitro studies were performed using a human foetal osteoblast cell
line (hFOBs) and primary human bone marrow stromal cells (hBMSCs). The results found pure
fucoxanthin inhibitory to cell proliferation in hFOBs at higher concentrations, whereas, the crude
extracts containing both polyphenols and fucoxanthin showed the ability to scavenge free radicals,
which masked this effect. None of the extracts tested showed strong pro-osteogenic effects in either
cell type tested, failing to support previously reported positive effects.
Keywords: brown seaweeds; fucoxanthin; osteogenic; bone regeneration; osteoporosis
1. Introduction
Phytochemicals from marine seaweed extracts offer promising novel treatment options for
osteoporosis and other bone-related diseases. Osteoporosis is associated with an increase in bone
resorption, which results in microarchitectural deterioration of bone tissue and overall bone fragility [1].
Clinical treatments, such as bisphosphonates, have proven most effective in the management of this
disease for over two decades [2], although side effects from high dosage (e.g., osteonecrosis of the
jaw) and long-term use (e.g., atypical fractures) are starting to emerge [2,3]. According to the National
Osteoporosis Foundation, in the U.S. alone, osteoporosis affects over 10 million people [4], resulting
in 3 million osteoporotic fractures in 2010, with associated medical costs estimated to be $25.3 billion
(for 2025) [1]. The respective costs in the U.K. were reported to be just over £2 billion in 2012, with
a projected exponential increase similar to the U.S. [5]. In a global context, it is estimated that over
75 million people suffer from this disease.
Marine bioprospecting has led to more studies investigating the osteogenic potential of seaweed
extracts and derivative pure compounds. Recently pro-osteogenic outcomes have been reported from
extracts obtained from red (Rhodophyta), green (Chlorophyta) and brown (Pheaophyta) seaweeds.
Carson et al. reported crude extracts from two red seaweeds to have significant osteogenic activities
in vitro and for bone formation in zebrafish larvae in vivo; however, the bioactive compound has yet to
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be isolated [6]. A study on green seaweeds suggested a correlation between the phenolic compounds
in the extracts and an increase in bone mineralisation when studied in vitro using osteoblast-like cells
and in vivo in zebrafish larvae [7]. Extracts [8] and coatings [9] containing phlorotannins, which are the
phenolic compounds in brown seaweeds, have also been reported to enhance osteoblast differentiation
and subsequent mineralisation. Other studies have reported that phlorotannin-rich extracts reduce
inflammation by the downregulation of pro-inflammatory cytokines [10,11]. In osteoarthritis,
pro-inflammatory cytokines, namely interleukin-1 alpha (IL-1α) and tumor necrosis factor-beta (TNF-β)
can compromise the repair by inhibiting the differentiation associated with alkaline phosphatase
(ALP) activity and the gene expression for ALP, α1(I) procollagen, runt-related transcription factor 2
(RUNX2) and osterix [12]. Although marine phenolic phytochemical compounds are evolutionarily and
chemically distinct from terrestrial compounds, several studies have reported the positive impact of
terrestrial phenolic compounds on bone metabolism, as summarised in a review by Habauzit et al. [13].
For example, phenolic compounds isolated from green tea epigallocatechin and soybean isoflavone
genistein with antioxidant capacity has been reported to induce osteoblast differentiation [14]. This
would suggest some commonality in their chemical structures is of therapeutic benefit in bone repair.
Osteoporosis and other bone diseases have been linked to oxidative stress [15]. Oxidative stress in
bone has been shown to reduce ALP, colony forming units (CFU) and RUNX2 differentiation markers.
Antioxidants have been shown to activate differentiation of osteoblasts and bone mineralisation, and
reduce osteoclast activity [14,15].
Brown seaweed extracts and purified compounds (e.g., fucoxanthin) from seaweeds have also
shown inhibitory activity against bone resorption [16,17]. Das et al. reported that fucoxanthin
suppressed osteoclastogenesis and induced apoptosis in osteoclast-like cells in vitro [16]. Under anoxic
conditions, fucoxanthin has been reported to act as an antioxidant, and to scavenge free radicals
and quench singlet oxygen in vitro [18]. This would suggest fucoxanthin has an antioxidant effect
as opposed to an anti-inflammatory effect [17]. Fucoxanthin is one of the few carotenoids that has
quenching abilities [17,18], it also has a unique structure (Figure 1), with an unusual allenic bond
(9 conjugated double bounds, a 5,6-monoepoxide) and oxygenic functional groups (e.g., hydroxyl) [19].
In bone repair, angiogenesis is pivotal for oxygenating bone cells [20], however, osteoporosis-reduced
bone mass can decrease blood flow [21,22], creating anoxic conditions that could enhance the free
radical activities of fucoxanthin. Fucoxanthin is considered to have many potential health benefits for
humans by helping to combat diseases such as obesity, malaria and bone disease, as summarised by
Peng et al. [23], however, research in these areas are very much in their infancy.
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2. Results
2.1. Chemical Analysis
2.1.1. HPLC Quantification of Fucoxanthin
HLPC chromatograms (Figure 2a) show that fucoxanthin (predominant peak) was eluted at a
retention time of approximately 1.8 min in a pure fucoxanthin standard, which is similar to that
reported in the literature [24]. The two brown seaweed extracts also eluted at approximately the same
time. Shoulder peaks were visible in both L. digitata and A. nodosum (Figure 2a), which are likely to
be 13′-cis isomers [24,25]. According to the HPLC analysis, L. digitata was found to have a higher
concentration of fucoxanthin per gram of seaweed at 7.83 mg/g compared to A. nodosum, which was
found to be 4.43 mg/g. Neither of the seaweed extracts were purified. The crude seaweed extracts
were reconstituted in ethanol at 1, 2.5, 5 and 10 µM concentrations of fucoxanthin for further analysis.
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2.1.2. Total Phenolic Content of L. digitata and A. nodosum Measured using Folin–Ciocalteu Method
Total phenolic content in the two crude extracts was quantified at each concentration of
fucoxanthin (Figure 2b) and were higher in A. nodosum extracts than that of the L. digitata extracts.
In A. nodosum, it ranged from 0.018 (±0.001) to 0.164 (±0.006) mg/mL, whereas in L. digitata it was in
the range of 0.002 (±0.0004) to 0.007 (±0.001) mg/mL. This is a reverse trend to that of fucoxanthin,
whereby the fucoxanthin concentration was higher in L. digitata.
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2.1.3. NMR Quantification of Total Fatty Acids in Extracts
1H NMR spectroscopy was used as a quantitative analytical method for total fatty acid content of
the crude extracts. Through the addition of a known concentration of an internal standard, vanillin,
to the samples, the total fatty acid residue content could be calculated by comparing the integration
value of the vanillin aldehyde proton at 9.8 ppm with that of the fatty acid C-2 methylene peaks
at 2.3 ppm. This methylene peak is in an area of the spectrum free from interfering signals and
is essentially constant whether the fatty acids are free carboxylic acids or extracted as lipid esters.
As can be seen clearly from the calculations (Table 1) based on the NMR spectra (Supplementary
Figure S1a,b), the sample obtained from A. nodosum shows a significantly higher fatty acid content
(≈ 8.8 × 10−5 mol/mL) than the sample from L. digitata (≈ 1.7 × 10−5 mol/mL).
Table 1. Fucoxanthin and total fatty acids content determined by 1H NMR spectroscopy data. For
original spectra, see Supplementary Figure S1.
Species Fucoxanthin(mmol/mL)
Total Fatty Acid
(mmol/mL) Ratio Fucoxanthin:Fatty Acids
A. nodosum 9.98 × 10−5 8,75 × 10−3 1:87
L. digitata 9.43 × 10−5 1.71 × 10−3 1:18
2.1.4. 2,2-Diphenyl-1-picrylhydrazyl DPPH Assay
The DPPH (2,2-diphenyl-1-picryl-hydrazyl-hydrate) assay was used to obtain the radical
scavenging ability of the seaweed extracts. The antioxidant ability was shown to be higher in
A. nodosum than L. digitata (Figure 3), which correlates to the higher phenolic content observed
from the Folin–Ciocalteu FC assay (Figure 2). No significant difference in antioxidant ability was
observed in A. nodosum at concentrations above 1 µM, which was found to be approximately 94%.
However, L. digitata showed an exponential increase in antioxidant ability from 13.91 (±0.24) to 42.48
(±0.48)% over the range of concentrations tested from 1 to 10 µM.
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Figure 3. Antioxidant ability of A. nodosum and L. digitata seaweed extracts determined using a
DPPH assay.
2.1.5. Dose Response of Pure Fucoxanthin Standard
Figure 4 shows the effect of pure fucoxanthin on the cellular activity of hFOBs using crystal
violet (Figure 4a) for cell proliferation and alkaline phosphatase (Figure 4b) for cell differentiation.
Four different concentrations (1, 2.5, 5 and 10 µM) were evaluated based on the results from a
study by Das et al. [16] over 7 days and compared to a 1% ethanol in medium control (the highest
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concentration of ethanol in the four preparations). For cell proliferation, there was no statistically
significant difference in cell proliferation between the treatment groups at day 1 (Figure 4a). By day
4 (Figure 4b), concentrations of 5 and 10 µM of pure fucoxanthin showed significantly reduced cell
number, whereas at 1 and 2.5 µM concentrations, cell proliferation was similar to the media only and
ethanol (EtOH 1%) controls. The same trend was observed at day 7 (Figure 4a), with the exception of
1 µM concentration, which showed a statistically significant (p = 0.016) increase in cell proliferation
compared to the ethanol (EtOH 1%) control. At day 1, there was higher cell proliferation in the
ethanol only controls compared to the media only control, whereas day 4 and 7 showed no significant
difference in cell proliferation between controls. These results also confirm that the concentration of
ethanol (1% v/v) used to solubilise the fucoxanthin into the media was not toxic to the cells.
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The relative ALP activity results show that cell differentiation was only supported by 1 µM of pure
fucoxanthin at day 7 (Figure 4b) and there was no significant difference between this concentration
and the controls. At day 14 (Figure 4b), the rate of differentiation for cells dosed with pure fucoxanthin
was found to be significantly lower than the controls, suggesting that fucoxanthin had an inhibitory
effect; cell differentiation was significantly lower in the groups treated with 2.5, 5 and 10 µM than the
ethanol (EtOH 1%) control (p = 0.011, p = 0.008 and p = 0.048, respectively).
2.1.6. Cell Proliferation
The results from the dose response experiment showed that higher concentrations of fucoxanthin
inhibited cell proliferation and suggested that lower doses may be stimulatory at later time points.
Therefore, for subsequent studies, a lower concentration of 0.5 µM was added, the highest concentration
of 10 µM was removed and an additional 2% ethanol control was included to account for a higher
amount of ethanol that was required to reconstitute the 5 µM A. nodosum extract.
When the extracts were tested on the hFOB cell line (Figure 5a–c), cell proliferation was observed
to be significantly higher that the relevant controls on day 1 for the pure fucoxanthin at 1 µM (with:
EtOH 1%, p = 0.004) and day 4 for the A. nodosum extract at a concentration of 5 µM (EtOH 2%,
p < 0.0001). At day 4, a significantly lower rate of cell proliferation was observed at concentrations of
2.5 and 5 µM of pure fucoxanthin with respect to all treatment groups (p < 0.0001). At day 7, A. nodosum
at a concentration of 1 µM had a significantly lower cell proliferation rate compared to the relevant
control (EtOH 1%, p = 0.006). Therefore, by day 7, a negative dose response was evident for L. digitata
and pure fucoxanthin but the effects of different doses of A. nodosum was more variable.
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2.1.7. Cell Differentiation
When hFOB cell lines were treated with extracts, no treatment groups stimulated ALP (alkaline
phosphatase activity) activity higher than the controls (Figure 6a,b). At both 7 and 14 days, a negative
dose response was observed in the pure fucoxanthin at concentrations above 2.5 µM where the lowest
ALP activity was observed. At 7 days, this was found to be significantly lower than the EtOH controls
for 2.5 µM (p = 0.008) and 5 µM (p = 0.009). Higher concentrations of 5 µM fucoxanthin in the crude
extracts of L. digitata was found to significantly inhibit ALP activity at both 7 (p = 0.040) and 14 days
(p = 0.020). The ALP activity of hBMSCs treated with all extracts was very variable. No treatment
groups stimulated ALP activity higher than the controls at either 7 or 14 days with the exception of
L. digitata at a concentration of 1 µM for 14 days (p = 0.013). After 14 days, a negative dose response
was observed in the pure fucoxanthin, whereas higher concentrations showed the lowest ALP activity.
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significant increase in concentration using one-way ANOVA with Bonferroni’s post hoc testing, with
p < 0.05 relative to respective controls. Blue box = hFOB Cells, Orange box = hBMSCs.
3. Discussion
There is a perception in the literature that fucoxanthin has potential therapeutic effects for bone
repair [23,26,27], yet only a few studies support this perception [16,26]. Koyama [26] assesses the
osteoblast potential of brown seaweed extracts that were extracted using a methanol extraction,
although the paper alludes to the presence of fucoxanthin, there is no chemical analysis provided to
definitively identify the compounds that stimulated the ALP response. Das et al. [16] focuses on the
ability of fucoxanthin to stimulate bone resorption, although also reports there was no reduction in
osteoblast cell viability of concentrations lower than 2.5 µM of pure fucoxanthin. Although this study
reports enhanced osteoclast activity, a subsequent study failed to replicate the results in vivo [17].
A few other studies have reported positive nutritional benefits of carotenoid supplements in bone
health [28–30]. The aim of this study was to test the osteogenic potential of pure fucoxanthin and crude
seaweed extracts containing both fucoxanthin and phenolic fractions (that have also been shown to
induce osteogenic effects).
In carotenoids, each double bond in its polyene chain can exist in two configurations, either
trans or cis. Most natural carotenoids are predominantly, or all, in the trans form, which is the major
fucoxanthin isomer [25]. A brown seaweed from New Zealand, Undaria pinnatifida, was reported to
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have trans-fucoxanthin as the major isomer (≈88%), with small amounts (≈9%) of 13-cis and 13′-cis
isomers [24,25]. The results from this study found the main isomer in L. digitata and A. nodosum to
be trans-fucoxanthin. Higher concentrations of fucoxanthin were observed in L. digitata (7.83 mg/g)
seaweed compared to A. nodosum (4.43 mg/g). A similar trend to Das et al. [16] was observed in this
study, whereby concentrations higher than 2.5 µM in pure fucoxanthin caused a reduction in cell
number in hFOB cell lines, either by direct cytotoxicity or by the inhibition of proliferation. In primary
hBMSC, pure fucoxanthin showed no significant difference in the cell number over the range tested
with respect to the relevant control. It is worth noting, however, that primary hBMSCs are much slower
growing that hFOBSs, therefore, it may take longer for the same effect to become visible. No inhibitory
effect was observed in the crude seaweed extracts, suggesting that other compounds, or the interaction
between several compounds, were having a protective effect. A methanol extraction was performed on
the samples, which removed any polar compounds present in the seaweed, e.g., membrane-associated
lipids and polar phenolic compounds. Therefore, fucoxanthin was not the only compound present
in the crude seaweed extracts. The crude extracts in this study were found to contain fucoxanthin,
phenolic compounds and fatty acids.
To date, identification of the phenolic structure and composition within seaweeds remains elusive
owing to challenges in the structural elucidation of these compounds [31,32]. This study has only taken
into consideration the total phenolic compounds found in the extracts. Positive correlations between
the total phenolic compounds and the antioxidant ability of seaweeds have previously been reported
in both A. nodosum and L. digitata [33]. Both phenolic compounds and fucoxanthin in brown seaweeds
are known for their high antioxidant activity [33–35], where their free radical scavenging capacity
can be higher than α-tocopherol, for example [17,18,34]. In this study, the total phenolic content and
the antioxidant ability of A. nodosum was found to be significantly higher than L. digitata at fixed
concentrations of fucoxanthin, although no direct correlation was observed between fucoxanthin (or
phenolic compounds) in the crude extracts and the DPPH radical scavenging activity in the A. nodosum
extract; a finding supported by others [34]. In this extract, the increase in phenolic compounds was
found to be directly proportional to the increase in fucoxanthin; however, there was no significant
difference in antioxidant ability above 1 µM.
In fucoxanthin, and the closely related metabolite fucoxanthinol, it has been shown that the
reactive allene functionality provides the most significant contribution to its radical scavenging and
antioxidant activity, but otherwise is similar to related polyene antioxidants such as α-tocopherol [36].
The mechanism of radical scavenging is very different for the phenolic phlorotannin compounds
and different chemical linkages [31] in the different types of phlorotannins found in the phenolic
fraction may result in variation in the antioxidant abilities between species. There are several types
of phlorotannin structure in seaweeds due to the different degrees of polymerisation and different
linkages; for example, aryl-aryl C–C linkages are only present in fucols, whereas phloroethols are
exclusively ether (C–O–C) linkages [37,38]. This structural difference could have contributed to the
significant differences in antioxidant activity between A. nodosum and L. digitata in this study.
A similar trend was observed in the total fatty acids extracted, whereby A. nodosum had a five-fold
greater concentration of fatty acids compared to L. digitata. When comparing the fatty acids in relation
to fucoxanthin, although L. digitata was found to have a higher concentration of fucoxanthin, the
ratio of fucoxanthin to fatty acids was lower. A. nodosum had a ratio of 1:87 (fucoxanthin:fatty acids),
whereas, L. digitata had a ratio of 1:18. Although, the phenolic content, antioxidant ability and fatty
acids content was significantly higher in A. nodosum, there was no marked difference in cell viability
and ALP expression or activity between A. nodosum and L. digitata in either cell type. This would
suggest that their combined form inhibits interaction with the cells, thus masking their effect. The
results indicate that pure fucoxanthin at higher concentrations had an inhibitory or cytotoxic effect on
cell growth; however, this was not observed in the crude extracts, supporting the theory that when the
compounds are combined, the activity of the specific compounds are masked.
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Studies by Surget et al. [7] and Ryu et al. [8] have both described phenolic compounds that
stimulate osteoblast differentiation by increasing production of ALP and bone mineralisation. Surget
et al., [7] tested a pure extract of phenolic compounds, whereas Ryu et al. [8] isolated specific
phlorotannins from the phenolic extract, and both studies found that the phenolic extracts enhanced
osteogenic activity in bone cells. The highest concentration of phenolic compounds tested in the crude
extract in this study was in the A. nodosum, which was 0.033 (±0.16) PGE mg/mL (0.032 (±0.16) GAE
mg/mL), which was significantly smaller than the lowest concentrations tested by Surget et al. [7]
that induced a positive osteogenic outcome. However, the concentration of phenolic compounds
was found to be directly proportional to the concentration of fucoxanthin. Therefore, to increase the
phenolic fraction in the crude extract, the concentration of fucoxanthin would also increase, potentially
resulting in inhibited cell growth or cytotoxicity when the crude fraction breaks down.
Our in vitro results have found no positive effects from crude extracts with fucoxanthin and
phenolic compounds, or from the pure fucoxanthin on cell number or on cell differentiation in hFOB
cell line or on primary hBMSCs from human donors. The cell type used in this study differs to the one
used by Das et al. who used an osteoblast-like cell line MC3T3-E1 [16], and Koyama [26] who used
primary BMSCs isolated from mice. Although immortalised cell lines are good for screening studies,
they do not fully resemble the behaviour of primary osteoblast cells [39]. Although, Koyama used
primary cells, the study did not characterise the chemistry of the extract; therefore, it is impossible to
correlate the results directly to fucoxanthin. In this study, higher concentrations of pure fucoxanthin
were found to inhibit cell viability in hFOBs but not in primary cells. In the crude extracts, it was
clear that something in the extract was masking this effect. Overall, this study was unable to find any
positive osteogenic outcomes at the concentrations tested.
4. Materials and Methods
4.1. Collection and Sample Preparation
Seaweed samples of Ascophyllum nodosum and Laminaria digitata were collected from Bangor
(54◦39′58.6”N 5◦39′53.4”W). The blade, which is the main part of the plant, was used in this study.
The seaweed samples were washed with water to remove all particulates and impurities. They were
then frozen overnight at −20 ◦C and lyophilised to remove any water and obtain the dry mass. Dried
seaweed was then ground to a particle size of 2 mm using a Polymix PX-MFC 90 D grinder (Kinematica,
35010021).
4.2. Chemistry
4.2.1. Extraction of Fucoxanthin
The extraction of fucoxanthin was performed using a modified version of Fung et al. method [40].
Seaweed samples (1 g, 2 mm particle size) were extracted with methanol (20 mL) at room temperature
in the dark. The extract was then filtered through cotton wool and the methanol was removed via
rotary evaporation with the water bath temperature kept below 40 ◦C to minimise degradation in the
extraction. The solid residue was then reconstituted in ethanol (2 mL) and the fucoxanthin content
was analysed using HPLC.
4.2.2. Calibration Curve of Fucoxanthin
Fucoxanthin (product of South Korea purchased from Sigma Aldrich, Spruce Street, St. Louis,
MO, USA) was dissolved in methanol and diluted to five different concentrations. The peak area was
measured for the five different concentrations and a calibration curve was plotted. The response to
the curve gave a linear trend with a regression value < 0.95. The gradient of the calibration curve was
used to calculate the fucoxanthin content in seaweed extracts.
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4.2.3. Seaweed Extract Analysis Using HPLC
Reconstituted seaweed extract in ethanol (0.5 mL) was analysed using HPLC with an 1100 high
performance liquid chromatography system from Agilent fitted with a photodiode array detector.
A Phenomenex C18 column (250 mm × 4.6 mm, 5 µm pore size) was used to separate the extract.
The programme used for detection was an isocratic programme using 100% HPLC-grade degassed
methanol for 15 min. The flow rate was set to 1 mL/min and the sample injection volume was 5 µL.
The detection wavelength was set to 450 nm.
4.2.4. Folin–Ciocalteu (FC) Analysis
Seaweed samples of different fucoxanthin contents were analysed using the FC assay for their
phenolic content. Samples were diluted to 10 µM, 5 µM, 2.5 µM and 1 µM with deionised water.
Diluted extracts (1 mL) were then mixed with a Folin–Ciocalteu reagent diluted with water (1:1 v/v)
and allowed to stand for 5 min. A total of 20% sodium carbonate (2.5 mL) was added to the solution
and allowed to develop for 40 min. The absorbance of the samples was measured at 755 nm. The
absorbances were converted to concentrations expressed in phloroglucinol equivalents (PGE mg/mL)
by using a phloroglucinol calibration curve.
4.2.5. Seaweed Extract Analysis by NMR
An aliquot of the methanol extract (3 mL) was dried and reconstituted in deuteriated chloroform
with an internal standard of vanillin at a concentration of 0.000427 mmol/mL. The aldehyde peak
of the vanillin internal standard was used to correlate the hydrogen’s alpha to the carboxylic acid.
This peak correlates to 2H atoms compared to the vanillin aldehyde peak of 1H, so the fatty acid peak
integration was first divided by 2. The concentration of fatty acids was then expressed in mmol/mL
by calculation from the internal standard.
4.2.6. DPPH Assay
An aliquot of the methanol extract was diluted to 10 µM, 5 µM, 2.5 µM and 1 µM of fucoxanthin
with methanol. Concentration of the fucoxanthin for dilution was carried out using HPLC from
Section 4.2.3. DPPH stock solution was prepared at 200 µM in methanol. Diluted extract (1 mL) was
then added to the DPPH stock solution, and a control using methanol was also used to validate the
method. The samples were then left for 20 min and then the absorbance was measured at 517 nm.
The scavenging activity was calculated as shown in Equation (1):
scavenging (%) = (1− Abssample
Abscontrol
)× 100 (1)
4.3. Biological Characterisation
4.3.1. Cell Preparation and Culture
Two cell types were used in this study: a human foetal osteoblast cell line (hFOBs), from LGC
Standards, (ATCC® CRL-11372™), Teddington, UK, and primary bone marrow derived mesenchymal
stem cells (hBMSCs) from human donors. For hFOB cell line, culture media was Dulbecco Modified
Eagle Medium (DMEM)/HAM F12 (Sigma-Aldrich, Dorset, UK) supplemented with 10% foetal bovine
serum, 0.6 mg/mL geneticin and 2 mM L-glutamine. Since hFOBs can spontaneously differentiate
into a mature osteoblastic phenotype at 39.5 ◦C, the cells were cultured at 33 ◦C throughout the
experiment (a temperature that permits proliferation [41]). To obtain hBMSCs, a bone marrow sample
was taken from the vertebral body of a patient undergoing pedicle screw insertion following ethical
approval and informed consent. The sample was processed to remove the white blood cell component,
which was then expanded in culture to passage 4 as previously described [6]. The culture medium
was α-MEM (Thermo Fisher Scientific, Loughborough, UK) supplemented with 10% Fetal Bovine
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Serum (FBS), 2 mM L-glutamine, 100 U/mL pen/strep for expansion and proliferation experiments.
For differentiation experiments, osteogenic medium was used which is as described above with the
addition of 50 µM ascorbate-2-phosphate, 10 µM β-glycerophosphate and 0.01 mM dexamethasone
(all Sigma-Aldrich, Dorset, UK).
For the first dose response experiment on hFOBS, commercially available fucoxanthin extract
(product of South Korea purchased from Sigma Aldrich, Spruce Street, St. Louis, MO, USA) was
dissolved in ethanol as a 10 µM stock solution and subsequently added to complete hFOB culture
medium to make up four treatment extract concentrations: 1, 2.5, 5 and 10 µM. This range was
influenced by the Das et al. study. Their study reported that concentrations higher than 2.5 µM
of pure fucoxanthin reduced cell proliferation in an osteoblast-like cell line MC3T3-E1 [16]. On the
basis of these results, in subsequent experiments, both cell types were challenged with extracts from
A. nodosum, L. digitata and commercially available fucoxanthin dissolved in ethanol and diluted with
culture medium to final concentrations of 0.5 µM, 1 µM, 2.5 µM and 5 µM. All test solutions had final
concentrations of ethanol of <1% with the exception of 5 µM A. nodosum, which had <2%. therefore 1%
EtOH and 2% EtOH were included as controls in addition to standard culture medium.
For both proliferation and differentiation experiments described below, cells were seeded at a
density of 1 × 104 cells/cm2 in 96-well plates and given a 24-h attachment period before the addition
of experimental treatments. Each treatment had four repeats. Cells were fed twice weekly by replacing
media containing experimental treatments.
4.3.2. Cell Proliferation
On days 1, 4 and 7, the cells were fixed in preparation for crystal violet staining, (to measure
cell proliferation) by the addition of 2% paraformaldehyde (Sigma-Aldrich, U.K.) solution (pH 6.8 in
phosphate-buffered saline (PBS)) for 30 min at room temperature. The solution was removed, cells
were washed with dH2O three times, then air dried. Following this, 100 µL of crystal violet solution
(Sigma-Aldrich, Dorset, UK) was added to each well (0.1% concentration in dH2O, filtered before use)
and left to stain for 30 min at room temperature. Next, the cells were washed with dH2O three times,
then air dried. Finally, 100 µL of 1 M acidified methanol was added to the wells to re-solubilise and
extract the dye. A Multiskan Spectrum microplate reader (Thermo Fisher Scientific, Loughborough,
UK) was subsequently used to measure absorbance at 585 nm, with acidified methanol used to blank
the treatments.
4.3.3. Cell Differentiation
On days 7 and 14, cellular alkaline phosphatase (ALP) activity was measured. Cell medium was
removed, cells were washed with alkaline buffer solution (5 M NaCl, 1 M Tris-Cl pH 9.5, 1 M MgCl2),
then 250 µL of 0.1% Triton X-100 in alkaline buffer was added. Plates were stored at −80 ◦C and
subjected to three freeze–thaw cycles to fully lyse all cells. Once defrosted, 50 µL of each lysate was
transferred, in duplicate, into a 96-well assay plate and supplemented with 200 µL of test solution
made of alkaline buffer solution and p-nitrophenyl phosphate substrate (both from Sigma-Aldrich,
U.K.). Standards were prepared from p-nitrophenol diluted with alkaline buffer solution. Each plate
was then covered in foil (to protect from light) and incubated for 30 min at 37 ◦C. A total of 50 µL
of stop solution (3 M NaOH) was added to the wells to terminate the reaction and absorbance was
then read at 405 nm using a Tecan GENios microplate reader A-5082, (Tecan, Grodig, Austria). Finally,
a PicoGreen assay (Thermo Fisher Scientific, UK) was conducted on the same cell lysates according to
manufacturer’s protocol to measure the amount of dsDNA. This allowed ALP activity to be normalised
to cell number.
4.4. Statistical Analysis
Statistical differences between groups were analysed using a one-way ANOVA with Bonferroni’s
post hoc testing using IMB SPSS v22. Significance was accepted if p < 0.05.
Mar. Drugs 2019, 17, 0 12 of 14
5. Conclusions
The results from this study question the reported pro-osteogenic effect of fucoxanthin and instead
suggest an inhibitory effect at higher concentrations. Crude extracts from two brown seaweeds
containing both polyphenols and fucoxanthin showed an ability to scavenge free radicals and were
protected in part against the inhibitory effects of higher concentrations of fucoxanthin, but also failed
to show strong pro-osteogenic effects.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/3/0/s1,
Figure S1: NMR spectra data for L. digitata and A. nodosum extracts.
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